Expressive

rs10278 - CALCOCO2

Magnitude 2.2 · 1 study on file

Reported associations

  • Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes - Unknown journal (n.d.) · Unknown authors · PubMed 29632382

    ABSTRACT: We aggregated coding variant data for 81,412 type 2 diabetes cases and 370,832 controls of diverse ancestry, identifying 40 coding variant association signals (p<2.2×10−7): of these, 16 map outside known risk loci. We make two important observations. First, only five of these signals are driven by low-frequency variants: even for these, effect sizes are modest (odds ratio ≤1.29). Second, when we used large-scale genome-wide association data to fine-map the associated variants in their regional context, accounting for the global enrichment of complex trait associations in coding sequence, compelling evidence for coding variant causality was obtained for only 16 signals. At 13 others, the associated coding variants clearly represent "false leads" with potential to generate

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Diet

  • whole grains, legumes, and fiber-rich vegetables Moderate

    Increased soluble fiber intake and reduced refined carbohydrates improve glycemic control and insulin sensitivity in Type 2 diabetes prevention

    30+ grams fiber daily; replace refined grains with whole grains

Exercise

  • aerobic and resistance training Moderate

    Regular physical activity enhances insulin sensitivity and glucose uptake to mitigate Type 2 diabetes risk from this genetic variant

    150+ minutes moderate aerobic per week, plus 2+ days resistance training

Screening

  • fasting glucose and HbA1c Moderate

    rs10278-C variant increases Type 2 diabetes risk independent of BMI through altered metabolic gene expression in adipose tissue and fibroblasts

    baseline screening at age 25-30, repeat every 1-3 years